C-reactive protein levels in patients at cardiovascular risk: EURIKA study

BMC Cardiovascular Disorders

Claudio Borghi⁷  Fernando Rodríguez-Artalejo⁴  Philippe Gabriel Steg³  Joep Perk^1,10  Jesús Medina⁵  Ogün Sazova²  Eliseo Guallar⁸  Guy De Backer⁶  Jean Dallongeville⁹  José R Banegas^1,11  Florence Tubach³  Carine Roy^1,12  Julian PJ Halcox¹ 

[1] Swansea University College of Medicine, Swansea, UK;AstraZeneca Global Medical Affairs, London, UK;Université Paris Diderot, Paris, France;Department of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid-IdiPAZ, Madrid, Spain;Medical Evidence Centre, Global Medical Affairs, AstraZeneca Farmacéutica Spain, Madrid, Spain;Department of Public Health, University of Ghent, Ghent, Belgium;Department of Internal Medicine, Ageing and Clinical Nephrology, University of Bologna, Bologna, Italy;Departments of Epidemiology and Medicine and Welch Center of Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA;Inserm U744, Institut Pasteur de Lille, Lille, France;School of Health and Caring Sciences, Linnaeus University, Kalmar, Sweden;Centros de Investigación Biomédica en Red (CIBER) of Epidemiology and Public Health (CIBERESP), Madrid, Spain;INSERM CIE 801 and Epidemiology and Clinical Research Department, Hôpital Bichat-Claude Bernard, Assistance Publique–Hôpitaux de Paris, Paris, France

关键词: Risk factors/global assessment;    Epidemiology;    Cardiovascular disease;    C-reactive protein;   

Others  :  855361
DOI  :  10.1186/1471-2261-14-25

 received in 2013-06-28, accepted in 2014-02-14,  发布年份 2014

【 摘 要 】

Background

Elevated C-reactive protein (CRP) levels are associated with high cardiovascular risk, and might identify patients who could benefit from more carefully adapted risk factor management. We have assessed the prevalence of elevated CRP levels in patients with one or more traditional cardiovascular risk factors.

Methods

Data were analysed from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA, ClinicalTrials.gov Identifier: NCT00882336), which included patients (aged ≥50 years) from 12 European countries with at least one traditional cardiovascular risk factor but no history of cardiovascular disease. Analysis was also carried out on the subset of patients without diabetes mellitus who were not receiving statin therapy.

Results

In the overall population, CRP levels were positively correlated with body mass index and glycated haemoglobin levels, and were negatively correlated with high-density lipoprotein cholesterol levels. CRP levels were also higher in women, those at higher traditionally estimated cardiovascular risk and those with greater numbers of metabolic syndrome markers. Among patients without diabetes mellitus who were not receiving statin therapy, approximately 30% had CRP levels ≥3 mg/L, and approximately 50% had CRP levels ≥2 mg/L, including those at intermediate levels of traditionally estimated cardiovascular risk.

Conclusions

CRP levels are elevated in a large proportion of patients with at least one cardiovascular risk factor, without diabetes mellitus who are not receiving statin therapy, suggesting a higher level of cardiovascular risk than predicted according to conventional risk estimation systems.

Trial registration

ClinicalTrials.gov Identifier: NCT00882336

【 授权许可】

   
2014 Halcox et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Tunstall-Pedoe H, Vanuzzo D, Hobbs M, Mahonen M, Cepaitis Z, Kuulasmaa K, Keil U: Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet 2000, 355(9205):688-700.
• [2]Palmieri L, Bennett K, Giampaoli S, Capewell S: Explaining the decrease in coronary heart disease mortality in Italy between 1980 and 2000. Am J Public Health 2010, 100(4):684-692.
• [3]Bjorck L, Rosengren A, Bennett K, Lappas G, Capewell S: Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002. Eur Heart J 2009, 30(9):1046-1056.
• [4]Hardoon SL, Whincup PH, Lennon LT, Wannamethee SG, Capewell S, Morris RW: How much of the recent decline in the incidence of myocardial infarction in British men can be explained by changes in cardiovascular risk factors? Evidence from a prospective population-based study. Circulation 2008, 117(5):598-604.
• [5]The global burden of disease: 2004 update http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf webcite
• [6]European cardiovascular disease statistics http://www.ehnheart.org/cvd-statistics.html webcite
• [7]Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Scholte op Reimer W, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A: European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007, 28(19):2375-2414.
• [8]Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njolstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM: Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003, 24(11):987-1003.
• [9]Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D, Bax J, Vahanian A, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Filippatos G, Funck-Brentano C, Hasdai D, Hoes A: ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32(14):1769-1818.
• [10]D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB: General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008, 117(6):743-753.
• [11]Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350(14):1387-1397.
• [12]Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB: Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000, 321(7255):199-204.
• [13]Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, Butterworth AS, Amouyel P, Assmann G, Bakker SJ, Barr EL, Barrett-Connor E, Benjamin EJ, Bjorkelund C, Brenner H, Brunner E, Clarke R, Cooper JA, Cremer P, Cushman M, Dagenais GR, D'Agostino RB Sr, Dankner R, Davey-Smith G, Deeg D, Dekker JM: C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012, 367(14):1310-1320.
• [14]Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB: C-reactive protein and coronary heart disease: a critical review. J Intern Med 2008, 264(4):295-314.
• [15]Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359(21):2195-2207.
• [16]Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001, 344(26):1959-1965.
• [17]Rodriguez-Artalejo F, Guallar E, Borghi C, Dallongeville J, De Backer G, Halcox JP, Hernandez-Vecino R, Jimenez FJ, Masso-Gonzalez EL, Perk J, Steg PG, Banegas JR: Rationale and methods of the European study on cardiovascular risk prevention and management in daily practice (EURIKA). BMC Public Health 2010, 10:382. BioMed Central Full Text
• [18]Banegas JR, Lopez-Garcia E, Dallongeville J, Guallar E, Halcox JP, Borghi C, Masso-Gonzalez EL, Jimenez FJ, Perk J, Steg PG, De Backer G, Rodriguez-Artalejo F: Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J 2011, 32(17):2143-2152.
• [19]Dallongeville J, Banegas JR, Tubach F, Guallar E, Borghi C, De Backer G, Halcox JP, Masso-Gonzalez EL, Perk J, Sazova O, Steg PG, Artalejo FR: Survey of physicians’ practices in the control of cardiovascular risk factors: the EURIKA study. Eur J Cardiovasc Prev Rehabil 2011, 19(3):541-550.
• [20]Huffman JC, Pollack MH: Predicting panic disorder among patients with chest pain: an analysis of the literature. Psychosomatics 2003, 44(3):222-236.
• [21]Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18(6):499-502.
• [22]Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120(16):1640-1645.
• [23]Ridker PM, Buring JE, Rifai N, Cook NR: Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007, 297(6):611-619.
• [24]Ridker PM, Glynn RJ: JUPITER, rosuvastatin, and the European medicines agency. Lancet 2010, 375(9731):2071.
• [25]Lloyd-Jones DM, Liu K, Tian L, Greenland P: Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med 2006, 145(1):35-42.
• [26]Morrissey RP, Diamond GA, Kaul S: The JUPITER trial: myth or reality? Curr Atheroscler Rep 2011, 13(5):413-421.
• [27]Sattar N, McConnachie A, O’Reilly D, Upton MN, Greer IA, Davey Smith G, Watt G: Inverse association between birth weight and C-reactive protein concentrations in the MIDSPAN family study. Arterioscler Thromb Vasc Biol 2004, 24(3):583-587.
• [28]Lakoski SG, Cushman M, Palmas W, Blumenthal R, D’Agostino RB Jr, Herrington DM: The relationship between blood pressure and C-reactive protein in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 2005, 46(10):1869-1874.
• [29]Timpson NJ, Lawlor DA, Harbord RM, Gaunt TR, Day IN, Palmer LJ, Hattersley AT, Ebrahim S, Lowe GD, Rumley A, Davey Smith G: C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet 2005, 366(9501):1954-1959.
• [30]Schindler TH, Cardenas J, Prior JO, Facta AD, Kreissl MC, Zhang XL, Sayre J, Dahlbom M, Licinio J, Schelbert HR: Relationship between increasing body weight, insulin resistance, inflammation, adipocytokine leptin, and coronary circulatory function. J Am Coll Cardiol 2006, 47(6):1188-1195.
• [31]Woodward M, Rumley A, Welsh P, MacMahon S, Lowe G: A comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease. J Thromb Haemost 2007, 5(9):1795-1800.
• [32]Boekholdt SM, Meuwese MC, Day NE, Luben R, Welch A, Wareham NJ, Khaw KT: Plasma concentrations of ascorbic acid and C-reactive protein, and risk of future coronary artery disease, in apparently healthy men and women: the EPIC-Norfolk prospective population study. Br J Nutr 2006, 96(3):516-522.
• [33]Davey Smith G, Timpson N, Lawlor DA: C-reactive protein and cardiovascular disease risk: still an unknown quantity? Ann Intern Med 2006, 145(1):70-72.
• [34]Koenig W, Lowel H, Baumert J, Meisinger C: C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004, 109(11):1349-1353.
• [35]Albert MA, Glynn RJ, Buring J, Ridker PM: C-reactive protein levels among women of various ethnic groups living in the United States (from the Women’s Health Study). Am J Cardiol 2004, 93(10):1238-1242.
• [36]Anand SS, Razak F, Yi Q, Davis B, Jacobs R, Vuksan V, Lonn E, Teo K, McQueen M, Yusuf S: C-reactive protein as a screening test for cardiovascular risk in a multiethnic population. Arterioscler Thromb Vasc Biol 2004, 24(8):1509-1515.
• [37]Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, Wians FH Jr, Grundy SM, de Lemos JA: Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 2005, 46(3):464-469.
• [38]Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E: Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001, 47(3):444-450.
• [39]Glynn RJ, MacFadyen JG, Ridker PM: Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. Clin Chem 2009, 55(2):305-312.
• [40]Chiriboga DE, Ma Y, Li W, Stanek EJ 3rd, Hebert JR, Merriam PA, Rawson ES, Ockene IS: Seasonal and sex variation of high-sensitivity C-reactive protein in healthy adults: a longitudinal study. Clin Chem 2009, 55(2):313-321.
• [41]Jonathan E, Derrick B, Emma L, Sarah P, John D, Jane A, Rory C: C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet 2011, 377(9764):469-476.
• [42]Sever PS, Poulter NR, Chang CL, Hingorani A, Thom SA, Hughes AD, Welsh P, Sattar N: Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2011, 33:486-494.